Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
Rheumatol Ther. 2023 doi: 10.1007/s40744-023-00548-y Epub ahead of print
Secukinumab reduced disease activity across a range of outcome measures by week 12, with sustained responses through 52 weeks.
Keywords:
Enthesitis in Patients with Psoriatic Arthritis Treated with Secukinumab or Adalimumab: a post hoc Analysis of the EXCEED Study
Rheumatology (Oxford).2023;kead181. doi 10.1093/rheumatology/kead181.
Results from the 52-week phase 3 EXCEED study showed that secukinumab and adalimumab both display similar efficacy in time to resolution of enthesitis, in patients with PsA, irrespective of baseline enthesitis severity and individual site distribution.
The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
Lancet. 2022. Epub ahead of print
Predefined analysis of FUTURE 5, the largest Phase 3 randomised trial of secukinumab in patients with PsA to date, demonstrates that secukinumab results in early, statistically significant, clinically meaningful, sustained improvements in PROs across all doses, compared with placebo.The fully human anti-interleukin 17A monoclonal antibody, secukinumab has shown clinical and radiographical efficacy in patients with PsA, yet the clinical significance of improvements across a wide variety of PROs r...